As part of our ongoing aim to bring you reports of new developments, we have added a study review which summarises key findings from Gladman et al. (2025), an analysis of the impact of bimekizumab on the symptoms and functional aspects that matter most to patients with psoriatic arthritis.
Independent commentary for the review has been provided by Dr Marie Feletar, a rheumatologist in Melbourne with a special interest in PsA.
Please login below to download this issue (PDF)